OncoCyte (OCX)

• Market cap: $35M
• 1 day: -0.95%
• 5 days: -5.45%
• 1 month: -5.88%
• 3 months: -33.33%
• 6 months: -36.97%
• Year to date: -10.73%
• 1 year: -39.71%
• 5 years: -96.56%
• 10 years: -98.71%
• Sector: Healthcare
• Industry: In Vitro & In Vivo Diagnostic Substances

About: OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers.

Employees: 46

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

0.41% less ownership

Funds ownership: 54.01% [Q2] → 53.6% (-0.41%) [Q3]

4% less capital invested

Capital invested by funds: $21.3M [Q2] → $20.4M (-$878K) [Q3]

13% less funds holding

Funds holding: 23 [Q2] → 20 (-3) [Q3]

50% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 4

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $4.25 104% upside
• Avg. target: $4.25 104% upside
• High target: $4.25 104% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

Needham Mike Matson 52% 1-year accuracy 64 / 122 met price target

104% upside $4.25

Buy Reiterated

13 Nov 2024